- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Undervalued based on future growth
U.S. Pharmaceuticals & Biotech Undervalued based on future growth
Results
12
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
12 companies
Elanco Animal Health
Market Cap: US$6.9b
An animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.
ELAN
US$16.48
7D
20.5%
1Y
26.9%
ADMA Biologics
Market Cap: US$4.4b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$16.75
7D
-10.4%
1Y
37.4%
Krystal Biotech
Market Cap: US$3.9b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
KRYS
US$136.10
7D
-11.5%
1Y
-24.5%
Alvotech
Market Cap: US$2.6b
Through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.
ALVO
US$8.44
7D
-6.8%
1Y
-22.6%
Organon
Market Cap: US$2.3b
Develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally.
OGN
US$9.11
7D
-6.1%
1Y
-53.4%
Harmony Biosciences Holdings
Market Cap: US$2.0b
A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
HRMY
US$34.19
7D
-2.8%
1Y
0.6%
SIGA Technologies
Market Cap: US$518.7m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$8.55
7D
29.3%
1Y
-6.9%
Protalix BioTherapeutics
Market Cap: US$117.8m
A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
PLX
US$1.51
7D
3.4%
1Y
45.2%
Outlook Therapeutics
Market Cap: US$80.6m
Operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications.
OTLK
US$1.84
7D
-6.1%
1Y
-75.2%
Earth Science Tech
Market Cap: US$51.5m
Together with its subsidies, focuses on health and wellness industry.
ETST
US$0.18
7D
-2.9%
1Y
2.7%
Neuphoria Therapeutics
Market Cap: US$14.7m
A clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia.
NEUP
US$7.75
7D
-4.4%
1Y
n/a
Minerva Neurosciences
Market Cap: US$12.6m
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.
NERV
US$1.80
7D
-4.0%
1Y
-39.3%